Skip to main content
Two women working )

About Us

Driven by Our Promise

CSL was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We see significant unmet needs in transplantation and are committed to delivering innovative solutions to address them.



 

Investment in our R&D

  • US $3.3 billion

    in R&D investments in the last 5 years (incl. Seqirus)

  • >1,700

    research and development employees

  • 40 Countries

    with CSL operations serving patients in 60+ countries

CSL Behring therapeutic area graphic

Commitment to Innovation

CSL Behring’s commitment to innovation is reflected in our R&D focus across three major areas including plasma therapies, recombinant proteins, and gene therapy. Additionally, our heritage and knowledge in other therapeutic areas such as Immunology and Haematology provides foundational expertise that can be leveraged in transplantation.

Learn more at CSLBehring.com